Mapi – Pharma Ltd.
We are a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex APIs, formulations and LCM products that target large markets. We are currently developing two LCM products for the treatment of multiple sclerosis (“MS”) and neuropathic pain. LCM products are new forms of marketed drugs which may offer advantages over existing formulations, such as improved patient compliance and reduced side effects, and allow extended patent and regulatory exclusivity of a marketed drug due to different formulations of product components, for example through depot or extended release formulations. Our LCM products seek to add value to products that are expected to go off-patent by integrating off-patent APIs with our formulations, resulting in a new final combination that is patentable.
|Address||16 Einstein St., P.O. Box 4113, Ness Ziona, IL 74140|
|View Prospectus:||Mapi – Pharma Ltd.|
|Revenues||$0.6 mil (last 12 months)|
|Net Income||$-6.7 mil (last 12 months)|
|Price range||$15.00 - $17.00|
|Est. $ Volume||$50.0 mil|
|Manager / Joint Managers||JMP Securities|
|CO-Managers||FBR/ Maxim Group|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|